Luis Paz-Ares

Country flagSpain

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (50)

Year:

2026

Effective strategies to reinvigorate the immune system are needed to improve outcomes in small cell lung cancer (SCLC). Targeting Src family kinases with dasatinib (Dasa) can elicit immunomodulatory effects in some cancer types. In this study, we explored the potential of combining Dasa with immune checkpoint blockade in SCLC. Although the SCLC models were refractory to anti–PD-1 or anti-CTLA4 monotherapy, anti–PD-1 and anti-CTLA4 combination immunotherapy (ITc) induced a significant antitumor response. Furthermore, the Dasa + ITc combination was superior to ITc or Dasa alone. Dasa + ITc activity was mediated by CD4 + T cells, MHC-II+ antigen-presenting cells, and NK cells, as depletion of these populations impeded the combination treatment antitumor efficacy. Increased tumor infiltration of CD4 + and CD8 + T cells, NK cells, M1-like macrophages, and CD11c + antigen-presenting cells and a reduction of regulatory T cells and M2-like macrophages were found in Dasa + ITc–treated mice. Dasa increased CCL5 in NK cells and reduced regulatory T-cell conversion from CD4 + lymphocytes. Dasa + ITc therapy elicited robust antitumor efficacy in three-dimensional cocultures of immune and SCLC cells. In vivo experiments showed that CCL5 was necessary for the Dasa + ITc response. In immunotherapy-treated patients with SCLC, a gene signature including CD4, CIITA, and tumor mutational burden predicted good prognosis. On-treatment CCL5 plasma levels were increased only in patients with long progression-free survival, and pretreatment secretomics identified cytokines related to myeloid cells significantly associated with poor prognosis. In summary, combining Dasa with immunotherapy represents a strategy to treat SCLC, with CCL5 as a cytokine that could serve to monitor response. Significance: Multikinase inhibitor and immune checkpoint blockade combination therapy overcomes the immunosuppressive tumor microenvironment in small cell lung cancer by activating CCL5 and costimulating CD4 + T cells, NK cells, and MHC-II + cells.

Year:

2025

Oncogene amplification and tumour suppressor deletion can drive tumour initiation, progression and treatment resistance. Detection at diagnosis often signals poor prognosis, but it can also enable opportunities for treatment with highly effective targeted therapies. Predicting the likelihood that a patient will acquire these driver alterations in the future using a genomic test represents an opportunity to realise the benefits of interventions earlier, potentially with preventative intent. Here, we present a forecasting framework that takes as input a DNA copy number profile and predicts whether the tumour will acquire an oncogene amplification or tumour suppressor deletion in the future. This framework leverages mutation rate estimates from the input tumour, alongside gene-specific selection coefficients derived from a large cohort of 7,880 tumours. We demonstrate feasibility using 7,042 single-time-point samples and longitudinally collected tumour pairs from 44 prostate and 100 lung cancers, identifying tumours that went on to acquire amplifications at a later time point with an average AUC of 0.87. We show potential clinical utility by forecasting poor prognosis in low-grade gliomas via CDK4/PDGFRA amplification or CDKN2A deletion, and osimertinib resistance in lung cancers via MET amplification. This study serves as a proof-of-concept for a new class of biomarker, wherein selective pressures and mutation-generating processes can be harnessed to anticipate future genomic alterations.

Year:

2025

Immunotherapy resistance in non–small cell lung cancer (NSCLC) may be mediated by an immunosuppressive microenvironment, which can be shaped by the mutational landscape of the tumor. Here, we observed genetic alterations in the PTEN/PI3K/AKT/mTOR pathway and/or loss of PTEN expression in >25% of patients with NSCLC, with higher frequency in lung squamous carcinomas (LUSC). Patients with PTEN-low tumors had higher levels of PD-L1 and PD-L2 and showed worse progression-free survival when treated with immunotherapy. Development of a Pten -null LUSC mouse model revealed that tumors with PTEN loss were refractory to antiprogrammed cell death protein 1 (anti–PD-1), highly metastatic and fibrotic, and secreted TGFβ/CXCL10 to promote conversion of CD4 + lymphocytes into regulatory T cells (Treg). Human and mouse PTEN-low tumors were enriched in Tregs and expressed higher levels of immunosuppressive genes. Importantly, treatment of mice bearing Pten -null tumors with TLR agonists and anti-TGFβ antibody aimed to alter this immunosuppressive microenvironment and led to tumor rejection and immunologic memory in 100% of mice. These results demonstrate that lack of PTEN causes immunotherapy resistance in LUSCs by establishing an immunosuppressive tumor microenvironment that can be reversed therapeutically. Significance: PTEN loss leads to the development of an immunosuppressive microenvironment in lung cancer that confers resistance to anti–PD-1 therapy, which can be overcome by targeting PTEN loss–mediated immunosuppression.

Year:

2025

Subgroup analysis of PFS by tTMB for (A) durvalumab plus EP versus EP and (B) durvalumab plus tremelimumab plus EP versus EP. In each panel, the shaded band shows the confidence interval for the ITT population; circle sizes are proportional to the number of events.

Year:

2024

Relationship between PD-L1 expression and tTMB score. (A) Box plots showing the distribution of tTMB score in patients by PD-L1 subgroup; (B) Venn diagram showing overlap between the tTMB ≥10 mut/Mb and PD-L1 TC or IC ≥1% subgroups. Percentages are calculated from the PD-L1 and tTMB BEP, i.e., patients who had both a PD-L1 and a tTMB result (n=275); samples from 171 patients had tTMB ≥10 mut/Mb and/or PD-L1 TC or IC ≥1%, while samples from 104 patients (37.8%) had both tTMB

Year:

2024

Subgroup analysis of PFS by PD-L1 TC and IC expression for (A) durvalumab plus EP versus EP and (B) durvalumab plus tremelimumab plus EP versus EP. In each panel, the shaded band shows the confidence interval for the ITT population; circle sizes are proportional to the number of events.

Year:

2024

Subgroup analysis of confirmed ORR by tTMB for (A) durvalumab plus EP versus EP and (B) durvalumab plus tremelimumab plus EP versus EP. In each panel, the shaded band shows the confidence interval for the ITT population; circle sizes are proportional to the number of responses.

Year:

2024

Subgroup analysis of confirmed ORR by PD-L1 TC and IC expression for (A) durvalumab plus EP versus EP and (B) durvalumab plus tremelimumab plus EP versus EP. In each panel, the shaded band shows the confidence interval for the ITT population; circle sizes are proportional to the number of responses. Groups are not plotted when there are ≤5 responses across both arms.

Year:

2024

Subgroup analysis of confirmed ORR by PD-L1 TC and IC expression for (A) durvalumab plus tremelimumab plus EP versus EP and (B) durvalumab plus EP versus EP. In each panel, the shaded band shows the confidence interval for the ITT population; circle sizes are proportional to the number of responses. Groups are not plotted when there are ≤5 responses across both arms.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (32)

Paul A. Bunn

Distinguished Professor

University of Colorado Cancer Center

UNITED STATES
View details

Marina Garassino

Prof

Università degli Studi di Torino

ITALY
View details

Alvaro González

Head Department

Clinica Universidad de Navarra

SPAIN
View details

Javier García-Corbacho

Head of Early Drug Development Unit

-

SPAIN
View details

Syed Hussain

Professor of Medical Oncology

University of Sheffield Medical School

UNITED KINGDOM
View details

Bartomeu Massuti

Head Department

Istituto Europeo di Oncologia

SPAIN
View details

Kai He

The Ohio State University Wexner Medical Center

UNITED STATES
View details

Charles Rudin

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Alfonso Calvo

Catedrático

Universidad de Navarra

SPAIN
View details

Jonathan W. Goldman

Associate Professor

UCLA

UNITED STATES
View details

Patricia Mondelo-Macía

-

SPAIN
View details

Amanda Parkes

University of Wisconsin-Madison

UNITED STATES
View details

Santiago Ponce Aix

Head of Therapeutic Innovation and Precision Medicine

Hospital Universitario 12 de Octubre

SPAIN
View details

Diego Serrano

Universidad de Navarra

SPAIN
View details

Geoff Macintyre

Group leader

Centro Nacional de Investigaciones Oncológicas

SPAIN
View details

Alvaro Ucero

Assistant Professor

Universidad Complutense de Madrid

SPAIN
View details

Anthony M. Joshua

Head of Department

University Health Network

CANADA
View details

Oscar Juan-Vidal

-

SPAIN
View details

Juan José Lasarte

Professsor

Universidad de Navarra

SPAIN
View details

Ramon Amat Ferrer

Senior Scientist

Vall d´Hebron Institute of Oncology

SPAIN
View details

Luis Alvarez-Vallina

Group Leader and Director of the Advanced Therapy Programme

Institut Hospital del Mar d'Investigacions Mèdiques

SPAIN
View details

Maxime Tarabichi

Group Leader

Université libre de Bruxelles

BELGIUM
View details

Hossein Borghaei

Professor and Chief, Thoracic Oncology

Fox Chase Cancer Center

UNITED STATES
View details

Mariano Provencio Pulla

Head of Medical Oncology Department at Puerta de Hierro University Hospital

Hospital Universitario Puerta del Hierro Majadahonda

SPAIN
View details

Eva Maria Garrido Martin

Profesor Ayudante Doctor Biología Celular

-

SPAIN
View details

Javier De Castro

Scientific Director

La Paz University Hospital

SPAIN
View details

Philipp J Jost

Chairman

Medical University of Graz

AUSTRIA
View details

Esther Conde

Hospital Universitario 12 de Octubre

SPAIN
View details

Giorgia Foggetti

Project leader

Ospedale San Raffaele

ITALY
View details

ENRIQUETA FELIP

Head Thoracic Oncology Unit (After Competitive Exam)

Hospital Universitari Vall d'Hebron

SPAIN
View details

Rossana Berardi

Associate Professor

Università Politecnica delle Marche

ITALY
View details

Afshin Dowlati

-

UNITED STATES
View details